Abstract
Cumulative scientific evidence gathered over the past ten years has confirmed the role of platelet GP IIb / IIIa inhibitors in reducing ischemic complications of patients undergoing percutaneous coronary intervention (PCI). Recently, mortality data available on more than 20,000 patients enrolled in randomized clinical trials suggest that GP IIb / IIIa blockade also improves short and long-term survival after PCI. Despite convincing arguments, GP IIb / IIIa inhibitors are still inconsistently administered in patients undergoing coronary intervention. The following review will discuss the scientific grounds and the principal controversies surrounding the use of these compounds in patients undergoing elective percutaneous coronary intervention.
Keywords: Coronary Intervention, IIIa inhibitors, GP IIb
Current Pharmaceutical Design
Title: GP IIb / IIIa Blockade in Elective Percutaneous Coronary Intervention
Volume: 10 Issue: 4
Author(s): Dery J.P., Harrington R.A. and Tcheng J.E.
Affiliation:
Keywords: Coronary Intervention, IIIa inhibitors, GP IIb
Abstract: Cumulative scientific evidence gathered over the past ten years has confirmed the role of platelet GP IIb / IIIa inhibitors in reducing ischemic complications of patients undergoing percutaneous coronary intervention (PCI). Recently, mortality data available on more than 20,000 patients enrolled in randomized clinical trials suggest that GP IIb / IIIa blockade also improves short and long-term survival after PCI. Despite convincing arguments, GP IIb / IIIa inhibitors are still inconsistently administered in patients undergoing coronary intervention. The following review will discuss the scientific grounds and the principal controversies surrounding the use of these compounds in patients undergoing elective percutaneous coronary intervention.
Export Options
About this article
Cite this article as:
Dery J.P. , Harrington R.A. and Tcheng J.E. , GP IIb / IIIa Blockade in Elective Percutaneous Coronary Intervention, Current Pharmaceutical Design 2004; 10 (4) . https://dx.doi.org/10.2174/1381612043453306
DOI https://dx.doi.org/10.2174/1381612043453306 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Hot and Potential Targets of Type 2 Diabetes Mellitus Treatment in Recent Decade
Current Drug Targets Intracellular Redox Signaling as Therapeutic Target for Novel Antiviral Strategy
Current Pharmaceutical Design Hypoxia Inducible Factor-1α, Endothelial Progenitor Cells, Monocytes,Cardiovascular Risk, Wound Healing, Cobalt and Hydralazine:A Unifying Hypothesis
Current Drug Targets Editorial: Resolution of Non-Alcoholic-Steatohepatitis. More than One Drug Needed?
Current Vascular Pharmacology Disruption of Circadian Rhythms and Sleep in Critical Illness: Potential Implications for Angiogenesis After Myocardial Infarction. A Review
Current Pharmaceutical Design Pulmonary Arterial Hypertension
Current Vascular Pharmacology Physical Function and Exercise in Older Patients with Cardiovascular and Respiratory Conditions
Current Pharmaceutical Design Novel Promising Therapeutic Agents in Multiple Sclerosis
Recent Patents on Inflammation & Allergy Drug Discovery Neuroprotection and Hypothermia in Infants and Children
Current Drug Targets Fibrinolytic Protease from Marine Streptomyces rubiginosus VITPSS1
Cardiovascular & Hematological Agents in Medicinal Chemistry Tuberculosis Therapeutics: Past Achievements, Present Road-Blocks and Future Perspectives
Letters in Drug Design & Discovery Pharmacogenomic Considerations of the Insertion / Deletion Gene Polymorphism of the Angiotensin I-Converting Enzyme and Coronary Artery Disease
Current Vascular Pharmacology Humoral Immunity in Heart Failure
Cardiovascular & Hematological Disorders-Drug Targets Patent Selections
Recent Patents on Cardiovascular Drug Discovery The Plasma and Tissue Kininogen-kallikrein-kinin System: Role in the Cardiovascular System
Current Medicinal Chemistry - Cardiovascular & Hematological Agents L-Arginine Availability as a Pathological Mechanism in Essential Hypertension, Chronic Renal and Heart Failure
Vascular Disease Prevention (Discontinued) Cytochrome P450s: Mechanisms and Biological Implications in Drug Metabolism and its Interaction with Oxidative Stress
Current Drug Metabolism Endothelial Changes in Individuals with Prehypertension
Current Hypertension Reviews Taking Risk Prediction to the Next Level. Advances in Biomarker Research for Atherosclerosis
Current Pharmaceutical Design Current Advancements in Aβ Luminescent Probes and Inhibitors of Aβ Aggregation
Current Alzheimer Research